Changeflow GovPing Pharma & Drug Safety Japan Science and Technology Agency V-ATPase In...
Routine Notice Added Final

Japan Science and Technology Agency V-ATPase Inhibitor Patent

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted patent US12599588B2 to Japan Science and Technology Agency for an inhibitor of Na+-translocating V-ATPase activity. The compound serves as an antibacterial agent and medicine with applications in antibacterial and screening methods. The patent application was filed January 15, 2020, contains 12 claims, and covers compounds with specific structural features including hydroxy, alkoxy, and amino substituents on phenyl groups.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted patent US12599588B2 to Japan Science and Technology Agency for compounds inhibiting Na+-translocating V-ATPase activity. The patented compounds have applications as antibacterial agents and medicines, including antibacterial and screening methods. The chemical structures include specified substituents on phenyl groups, with R1 representing hydroxy, alkoxy, haloalkoxy, dialkylamino, heterocyclic amine, carboxylic acid amide, bromine, iodine, or hydrocarbon groups.

For pharmaceutical companies developing antibacterial agents, this patent grants exclusive rights to the Japan Science and Technology Agency for V-ATPase inhibitor compounds. Companies pursuing similar compounds or methods should conduct freedom-to-operate analyses to assess potential infringement risks. The patent's 12 claims provide broad protection for the chemical compositions and their applications.

What to do next

  1. Monitor patent database for related patents
  2. Review patent claims for freedom-to-operate analysis

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Inhibitor for V-ATPase activity, antibacterial agent, medicine, antibacterial method and screening method

Grant US12599588B2 Kind: B2 Apr 14, 2026

Assignee

Japan Science and Technology Agency

Inventors

Takeshi Murata, Kouki Shimizu, Fabiana Lica Yakushiji, Katsuhiko Moriyama

Abstract

An inhibitor for Na+-translocating V-ATPase activity including a compound represented by where R1 represents a group selected from a hydroxy group, an alkoxy group, and a haloalkoxy group, each bonded to an adjacent phenyl group via oxygen, or a group selected from a dialkylamino group, a heterocyclic amine, and a carboxylic acid amide group, each bonded to an adjacent phenyl group via nitrogen, or represents bromine, iodine, or a straight-chain hydrocarbon group. R2 represents hydrogen or a haloalkoxy group. Z1 represents an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aromatic hydrocarbon group, or a heterocyclic group, each optionally having an arbitrary substituent and having a structure containing a double bond selected from between the group and an adjacent phenyl group. The symbol * represents a bond to the adjacent phenyl group.

CPC Classifications

C07D 401/12 C07D 401/14 C07D 405/14 A61P 35/00 A61K 31/4439 A61K 31/444 A61K 31/497

Filing Date

2020-01-15

Application No.

17423598

Claims

12

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599588B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Antibacterial compound development Drug discovery
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!